Abstract

Objective: To evaluate clinical and microbiological effectiveness of the combined preparation Simprazole® (ornidazole 500 mg + ciprofloxacin 500 mg) in patients with skin and soft tissue infections.Material and methods. This prospective study was conducted in a multidisciplinary hospital from February to May 2023. Outcomes after treating patients with purulent wounds of the skin and soft tissues of various origins and location were analyzed. Patients with the extremely severe infectious processes and decompensated diseases of cardiopulmonary, respiratory and other vital systems were excluded from the study. Resistance and sensitivity of isolated strains to antibiotics was assessed in patients’ tests in 7 or 14 days. Patients with strains sensitive to ciprofloxacin were enrolled in the study. In addition to the antibacterial therapy, they had local treatment (dressings and wound debridement).Results. The involved 60 patients had a combined surgical treatment in the hospital. Clinical and laboratory findings have shown that the combined preparation consisting of ciprofloxacin and ornidazole has a high clinical and bacteriological effectiveness (95 and 96.7 %, respectively) in patients with purulent wounds of the skin and soft tissues regardless of pathogens etiology (aerobic or anaerobic) and anaerobic component, if these pathogens are sensitive to ciprofloxacin. The discussed preparation is well tolerated in 99 % of cases; no registered adverse reactions.Conclusion. The combined preparation Simprazole® (500 mg of ornidazole and 500 mg of ciprofloxacin) has a wide spectrum of action and original mechanisms of impact at microbes. It is an effective and safe drug for treating skin and soft tissue infections from both clinical and microbiological points of view.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call